Home / Business and Economy / Indian Pharma Eyes US Growth Beyond Generics
Indian Pharma Eyes US Growth Beyond Generics
25 May
Summary
- Indian drugmakers are expanding US pipelines and manufacturing.
- Investments target respiratory products, injectables, and rare diseases.
- Companies pursue differentiated filings and local manufacturing for US market.
Indian pharmaceutical companies are intensifying their focus on the United States market, which remains the largest global market. Rather than scaling back, these companies are actively expanding their product pipelines and manufacturing capacities within the US. This strategic shift involves increased investment in high-growth areas such as respiratory products, injectables, biosimilars, and therapies for rare diseases.
Furthermore, several Indian drugmakers are exploring and utilizing differentiated regulatory pathways, including 505(b)(2) filings. They are also strategically establishing local manufacturing capabilities closer to the American market. These efforts aim to move beyond commoditized oral generics and secure a stronger, more diversified position for future growth in the US.
